CVRx Issues 2026 Outlook and Expands Loan Facility

Claim 70% Off TipRanks PremiumUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potentialThe latest announcement is out from CVRx ( (CVRX) ). On January 12, 2026, CVRx reported preliminary unaudited results indicating fourth-quarter 2025 revenue of $15.9 million to $16.1 million, up 4% to 5% year over year, and full-year 2025 revenue of $56.5 million to $56.7 million, up 10% to 11%, alongside modest expansion of its implanting center network and U.S. sales territories and year-end cash of $75.7 million. The company issued 2026 guidance calling for revenue of $63 million to $67 million, gross margins of 84% to 86% and operating expenses of $103 million to $107 million, while benefiting from new Category I CPT codes effective January 1, 2026, which management highlighted as easing adoption barriers for Barostim. Operationally, CVRx secured additional financial flexibility by amending its Innovatus-led term loan facility on January 9, 2026, doubling potential borrowings to $100 million, extending interest-only payments for up to five years subject to milestones, and pushing maturity to May 2031, with $60 million outstanding after a new $10 million draw. Strategically, the FDA’s November 2025 approval of the BENEFIT-HF trial design and the company’s subsequent CMS coverage application mark a major clinical investment, as the large, multicenter randomized study of Barostim in an expanded heart failure population could, if successful, significantly enlarge the device’s U.S. addressable market and reinforce CVRx’s competitive position in heart failure neuromodulation. The most recent analyst rating on (CVRX) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on CVRx stock, see the CVRX Stock Forecast page. Spark’s Take on CVRX Stock According to Spark, TipRanks’ AI Analyst, CVRX is a Neutral. CVRx’s overall stock score is primarily impacted by its financial performance challenges, including high operating losses and negative cash flows. While the earnings call provided some positive insights, such as revenue growth and strategic progress, the technical indicators suggest potential bearish momentum. The valuation remains a concern due to the negative P/E ratio and lack of dividend yield. To see Spark’s full report on CVRX stock, click here. More about CVRx CVRx, Inc. is a commercial-stage medical device company specializing in neuromodulation solutions for cardiovascular disease. Its flagship product, Barostim, is an implantable device that delivers electrical pulses to baroreceptors in the carotid artery to rebalance the autonomic nervous system and alleviate heart failure symptoms. Barostim holds FDA approval for heart failure in the U.S., has received FDA Breakthrough Device designation, and is MDR-compliant with CE Mark approval for heart failure and resistant hypertension in the European Economic Area, positioning CVRx in the niche but growing market for device-based heart failure therapies. Average Trading Volume: 213,624 Technical Sentiment Signal: Sell Current Market Cap: $221.5M For an in-depth examination of CVRX stock, go to TipRanks’ Overview page.